Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells

International Journal of Cancer

Volumn 112, Issue 4, 2004, Pages 693-700

  Banerjee, Rajkumar ^a,b   Tyagi, Pradeep ^a   Li, Song ^a   Huang, Leaf ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Anisamide; Drug targeting; PEG liposome; Prostate cancer; Sigma receptor

Indexed keywords

ANISAMIDE; DOXORUBICIN; DRUG CARRIER; HALOPERIDOL; LIGAND; LIPOSOME; MACROGOL; PALMITOLEYLPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DERIVATIZATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG TARGETING; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TOXICITY;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; BENZAMIDES; DOXORUBICIN; HUMANS; INFUSIONS, INTRAVENOUS; LIGANDS; LIPOSOMES; MALE; MOLECULAR WEIGHT; PROSTATIC NEOPLASMS; RECEPTORS, SIGMA; TUMOR CELLS, CULTURED;

EID: 7044231886     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20452     Document Type: Article

References (36)

1. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990;42:355-402.
2. Wolfe SA Jr, Culp SG, De Souza EB. Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989;124:1160-72.
3. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994;268:9-18.
4. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995;55:408-13
5. John CS, Bowen WD, Saga T, Kinuya, S, Vilner BJ, Baumgold J, Paik CH, Reba RC, Neumann RD, Varma VM. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2- piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 1993;34:2169-75.
6. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J Med Chem 1994;37:1737-9.
7. 125I]-N-(N- benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 1995;55:3022-7.
8. 125I]N-[2-(4-iodophenyl)ethyl]-N- methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors. Nucl Med Biol 1996;23:761-6.
9. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 1999;59:4578-83.
10. 125I]MBA) for imaging breast cancer. Nucl Med Biol 1999;26:377-82.
11. Huang A, Huang L, Kennel SJ. Monoclonal antibody covalently coupled with fatty acid: a reagent for in vitro liposome targeting. J Biol Chem 1980;255:8015-8.
12. Huang A, Tsao YS, Kennel SJ, Huang L. Characterization of antibody covalently coupled to liposomes. Biochim Biophys Acta 1982;716:140-50.
13. Huang A, Kennel SJ, Huang L. Interactions of immunoliposomes with target cells. J Biol Chem 1983;258:4034-40.
14. Hughes BJ, Kennel S, Lee R, Huang L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res 1989;49:6214-20.
15. Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997;413:177-80.
16. HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92:1327-31.
17. de Menezes DEL, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal DOX to human B-cell lymphoma. Cancer Res 1998;58:3320-30.
18. Connor J, Huang L. Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. J Cell Biol 1985;101:582-9.
19. Connor J, Huang, L. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res 1986;46:3431-5.
20. Sullivan SM, Huang L. Heat-sensitive immunoliposomes: preparation and characterization. Biochim Biophys Acta 1985;812:116-26.
21. Ho RJY, Rouse B, Huang L. Target- sensitive immunoliposomes: preparation and characterization. Biochemistry 1986;25:5500-6.
22. Maruyama K, Kennel SJ, Huang L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci USA 1990;87:5744-8.
23. Mori A, Kennel SJ, Huang L. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm Res 1993;10:507-14.
24. Mori A, Kennel SJ, Waalkes MVB, Scherphof GL, Huang L. Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O- dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung metastasis model. Cancer Chemother Pharmacol 1995;35:447-57.
25. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235-7.
26. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly(ethylene glycol) derivatized phospholipid into preformed liposomes results in prolonged in vivo circulation time. FEBS Lett 1996;386:243-6.
27. Leffler MT, Adams R. Aminophenyl-2-oxazolines as local anesthetics. J Am Chem Soc 1937;59:2252-8.
28. Greenwald RB, Gilbert CW, Pendri A, Conover CD, Xia J, Martinez A. Drug delivery systems: water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 1996;39:424-31.
29. Mayer LD, Tai LCL, Bally MB, Mitilene GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing Doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990;1025:143-51.
30. Ablordeppey SY, Fischer JB, Glennon RA. Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? Bioorg Med Chem 2000;8:2105-11.
31. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001;1513:207-16.
32. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 2001;15:215-24.
33. Vingerhoeds MH, Steerenberg PA, Hendriks JJ, Dekker LC, Van Hoesel QG, Crommelin DJ, Storm G. Immunoliposome-mediated targeting of Doxorubicin to human ovarian carcinoma in vitro and in vivo. Br J Cancer 1996;74:1023-9.
34. Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB. Antibody targeting of Doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60:6942-9.
35. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of Doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6:1949-57.
36. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal Doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002;100:594-602.